Form S-3 Orexigen Therapeutics,
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
JMP Securities Downgrades Orexigen Therapeutics (OREX) to Market Perform
March 16, 2016 6:34 AM EDTJMP Securities downgraded Orexigen Therapeutics (NASDAQ: OREX) from Market Outperform to Market Perform and removed its price target (prior $2.00).
For an analyst ratings summary and ratings history on Orexigen Therapeutics click here. For more ratings news on Orexigen Therapeutics click here.
Shares of Orexigen Therapeutics closed at $0.64 yesterday.
... MoreOrexigen Therapeutics (OREX) Files $150M Mixed Shelf
March 15, 2016 5:26 PM EDTOrexigen Therapeutics (NASDAQ: OREX) filed a registration with the U.S. SEC to sell up to $150 million worth of mixed securities.
... More